Skip to main content

Table 4 Studies on anticoagulation resumption after ICH

From: Patients with venous thromboembolism after spontaneous intracerebral hemorrhage: a review

First author

(year)

Design

ICH type

N of pts

Indications

Timing of resumption

Anticoagulants

Comparator

Risk of TE

Risk of recurrent ICH

Majeed [83]

(2010)

Retrospective

Anticoagulation-related

234

AF, MV, VTE

Median 5.6 weeks

Warfarin

Without AC

Not mentioned

8 vs. 10 (HR 5.6, 95%CI 1.8–17.2)

Yung [84]

(2012)

Retrospective

Anticoagulation-related

284

AF, MV, VTE

Within a month

Warfarin

Without AC

Not mentioned

15.4% vs. 15.0% (P = 0.94)

Kuramatsu [85]

(2015)

Retrospective

Anticoagulation-related

719

AF, MV, VTE

Median 31 days

OAC

Without AC

5.2% vs. 15.0% (P < 0.001)

8.1% vs. 6.6% (P = 0.48)

Witt [86]

(2015)

Retrospective

Anticoagulation-related

160

AF, MI, MV, IS, VTE

Median 14 days

Warfarin

Without AC

3.7% vs. 12.3% (P = 0.092)

7.6% vs.3.7% (P = 0.497)

Ottosen [82]

(2016)

Retrospective

Spontaneous

2978

AF, IS, MI, MV, PAD, VTE

Not mentioned

OAC

Without AC

Lower (HR 0.58, 95%CI 0.35–0.97)

Not increased (HR 0.90, 95%CI 0.44–1.82)

  1. N of pts number of patients; AF atrial fibrillation; MV mechanical valves; MI myocardial infarction; IS ischemic stroke; PAD peripheral vascular disease; OAC oral anticoagulants; AC anticoagulants; TE thrombotic events; HR hazard ratio